Antidepressant and nootropic activity of aqueous extract of Bougainvillea glabra

The aim of this analysis was to assess antidepressant & nootropic capacity of Bougainvillea Glabra aqueous extract (BGAE). Forced swim test, tail suspension test, & tetrabenazine mediated catalepsy & ptosis models were used to assess BGAE's antidepressant efficacy in mice at doses of 250 & 500 mg/kg orally. Morris water maze with elevated plus maze (EPM) was used to test nootropic behaviour. Normal medications for antidepressant & nootropic function were imipramine (25 mg/kg) & piracetam (300 mg/kg), respectively. Antioxidant assays such as DPPH & TBARS were used to validate antidepressant & nootropic function. When comparison to car, pre-treatment with BGAE resulted in substantial dose-dependent decrease in immobility time in both FST & TST. (P0.005) Tetrabenazine-induced catalepsy & ptosis were both decreased dramatically. Furthermore, in MWM & EPM, BGAE demonstrated dose-dependent cognitive enhancing behaviour. In DPPH assay, BGAE had IC50 of 17.39 g/ ml, & in TBARS assay, it had IC50 of 398.71 gm/ ml. BGAE has antidepressant & nootropic activities that are equivalent to imipramine & piracetam at doses of 250 & 500 mg/kg, respectively, which may be due to its effect on neurotransmitters & antioxidant function.